Zinger Key Points
- Owens & Minor says Q1 was in line with expectations, with top-line growth in both segments and improved profitability.
- Patient Direct segment delivered mid-single-digit top-line growth while navigating the unique challenges in the quarter.
- Get Monthly Picks of Market's Fastest Movers
On Friday, Owens & Minor Inc. OMI reported first-quarter adjusted EPS of $0.19, up from $0.05 a year ago and beating the consensus of $0.18.
Adjusted net income of $14.9 million was higher than $3.6 million a year ago.
The company reported sales of $2.61 billion, up 4% Y/Y, almost in line with the consensus of $2.61 billion.
Patient Direct revenue was $638 million, up 5% year over year. Products & Healthcare Services revenue was nearly $2 billion, up 3%.
“Our solid performance in the first quarter was in line with our expectations, as we delivered top-line growth in both segments, adjusted operating margin expansion, and improved year-over-year profitability,” said Edward A. Pesicka, President & CEO.
“In our Products & Healthcare Services segment, we onboarded new customers, grew same-store sales, and invested in inventory to support our new wins and provide best-in-class service levels. On the heels of double-digit growth in the prior years, our Patient Direct segment delivered mid-single-digit top-line growth while navigating the unique challenges that occurred in the quarter, demonstrating the strength of our team and the effectiveness of our go-to-market strategies,” concluded Mr. Pesicka.
Adjusted operating income from $47.7 million to $57.4 million, with adjusted EBITDA of $116.3 million, up from $108.7 million a year ago.
The first quarter’s gross margin improved 79 basis points to 20.5%.
Guidance: Owens & Minor reaffirms 2024 revenue guidance of $10.5 billion-$10.9 billion versus the consensus of $10.66 billion.
The company continues to expect 2024 adjusted EPS of $1.40-$1.70 versus the consensus of $1.57.
Price Action: OMI shares are down 20.30% at $19.53 at last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.